News
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback